Intensity-modulated radiation therapy for total body irradiation in hematopoietic stem cell transplantation: Phase II study

Phase 2

• Conditions: hematopoietic malignancy

• Registration Number: JPRN-UMIN000017563
• Lead Sponsor: The University of Tokyo Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-14
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

With serious complication. With simultaneous double cancer or heterochronic double cancer in last 5 years. With previous history of radiation. Not being able to remain at rest during treatment. With technical problem for intensity-modulated radiation therapy. Being in pregnancy. Judging inadequate by any medical, psychological or other reasons.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of grade 3 or worse adverse events, based on CTCAE ver. 4.0, from 3 months to 1 year after total body irradiation.

Secondary Outcome Measures

Name	Time	Method
Reccurence-free survial, overall survival, graft survival rate, time to graft survival, and frequency of grade 3 or worse adverse events in full observation period.